Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma

Christopher Hartley; Daniel Rowan; Xiuxu Chen; Luisa Gomez-Arellano; Anna Marie West; Kiyoko Oshima; Alexander Craig Mackinnon

doi:10.1016/j.plabm.2020.e00171

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma

Christopher Hartley, Daniel Rowan, Xiuxu Chen, Luisa Gomez-Arellano, Anna Marie West, Kiyoko Oshima, Alexander Craig Mackinnon

Research output: Contribution to journal › Article › peer-review

Abstract

Secreted Protein Acid and Rich in Cysteine (SPARC) is an extracellular glycoprotein secreted by fibroblasts and osteoblasts in normal tissues. SPARC overexpression occurs in multiple tumors including pancreatic ductal adenocarcinoma (PDAC) and may predict favorable response to nab-paclitaxel. The prognostic significance of SPARC expression in PDAC is unclear – some reports indicate SPARC overexpression associates with poor outcomes and others find no correlation. Considering neoadjuvant therapy enhances the stromal fibrosis of PDAC and taking into account that SPARC is a component of PDAC stromal fibrosis, we hypothesized that SPARC expression would be greater in neoadjuvant-treated versus treatment-naive PDAC. Quantitative immunohistochemistry was used to measure SPARC expression in resected PDAC in 74 cases of neoadjuvant treated PDAC and 95 cases of treatment-naïve PDAC. SPARC expression was increased 54% in neoadjuvant treated PDAC compared to treatment-naïve PDAC. These data indicate that increased SPARC expression correlates with neoadjuvant therapy in PDAC.

Original language	English (US)
Article number	e00171
Journal	Practical Laboratory Medicine
Volume	21
DOIs	https://doi.org/10.1016/j.plabm.2020.e00171
State	Published - Aug 2020
Externally published	Yes

Keywords

Adjuvant therapy
Digital image analysis
Immunohistochemistry
Neoadjuvant therapy
Pancreatic cancer
SPARC

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Clinical Biochemistry

Access to Document

10.1016/j.plabm.2020.e00171

Cite this

@article{9e5832da5ccb4b25934fed6c1078e622,

title = "Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma",

abstract = "Secreted Protein Acid and Rich in Cysteine (SPARC) is an extracellular glycoprotein secreted by fibroblasts and osteoblasts in normal tissues. SPARC overexpression occurs in multiple tumors including pancreatic ductal adenocarcinoma (PDAC) and may predict favorable response to nab-paclitaxel. The prognostic significance of SPARC expression in PDAC is unclear – some reports indicate SPARC overexpression associates with poor outcomes and others find no correlation. Considering neoadjuvant therapy enhances the stromal fibrosis of PDAC and taking into account that SPARC is a component of PDAC stromal fibrosis, we hypothesized that SPARC expression would be greater in neoadjuvant-treated versus treatment-naive PDAC. Quantitative immunohistochemistry was used to measure SPARC expression in resected PDAC in 74 cases of neoadjuvant treated PDAC and 95 cases of treatment-na{\"i}ve PDAC. SPARC expression was increased 54% in neoadjuvant treated PDAC compared to treatment-na{\"i}ve PDAC. These data indicate that increased SPARC expression correlates with neoadjuvant therapy in PDAC.",

keywords = "Adjuvant therapy, Digital image analysis, Immunohistochemistry, Neoadjuvant therapy, Pancreatic cancer, SPARC",

author = "Christopher Hartley and Daniel Rowan and Xiuxu Chen and Luisa Gomez-Arellano and West, {Anna Marie} and Kiyoko Oshima and Mackinnon, {Alexander Craig}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = aug,

doi = "10.1016/j.plabm.2020.e00171",

language = "English (US)",

volume = "21",

journal = "Practical Laboratory Medicine",

issn = "2352-5517",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma

AU - Hartley, Christopher

AU - Rowan, Daniel

AU - Chen, Xiuxu

AU - Gomez-Arellano, Luisa

AU - West, Anna Marie

AU - Oshima, Kiyoko

AU - Mackinnon, Alexander Craig

PY - 2020/8

Y1 - 2020/8

N2 - Secreted Protein Acid and Rich in Cysteine (SPARC) is an extracellular glycoprotein secreted by fibroblasts and osteoblasts in normal tissues. SPARC overexpression occurs in multiple tumors including pancreatic ductal adenocarcinoma (PDAC) and may predict favorable response to nab-paclitaxel. The prognostic significance of SPARC expression in PDAC is unclear – some reports indicate SPARC overexpression associates with poor outcomes and others find no correlation. Considering neoadjuvant therapy enhances the stromal fibrosis of PDAC and taking into account that SPARC is a component of PDAC stromal fibrosis, we hypothesized that SPARC expression would be greater in neoadjuvant-treated versus treatment-naive PDAC. Quantitative immunohistochemistry was used to measure SPARC expression in resected PDAC in 74 cases of neoadjuvant treated PDAC and 95 cases of treatment-naïve PDAC. SPARC expression was increased 54% in neoadjuvant treated PDAC compared to treatment-naïve PDAC. These data indicate that increased SPARC expression correlates with neoadjuvant therapy in PDAC.

AB - Secreted Protein Acid and Rich in Cysteine (SPARC) is an extracellular glycoprotein secreted by fibroblasts and osteoblasts in normal tissues. SPARC overexpression occurs in multiple tumors including pancreatic ductal adenocarcinoma (PDAC) and may predict favorable response to nab-paclitaxel. The prognostic significance of SPARC expression in PDAC is unclear – some reports indicate SPARC overexpression associates with poor outcomes and others find no correlation. Considering neoadjuvant therapy enhances the stromal fibrosis of PDAC and taking into account that SPARC is a component of PDAC stromal fibrosis, we hypothesized that SPARC expression would be greater in neoadjuvant-treated versus treatment-naive PDAC. Quantitative immunohistochemistry was used to measure SPARC expression in resected PDAC in 74 cases of neoadjuvant treated PDAC and 95 cases of treatment-naïve PDAC. SPARC expression was increased 54% in neoadjuvant treated PDAC compared to treatment-naïve PDAC. These data indicate that increased SPARC expression correlates with neoadjuvant therapy in PDAC.

KW - Adjuvant therapy

KW - Digital image analysis

KW - Immunohistochemistry

KW - Neoadjuvant therapy

KW - Pancreatic cancer

KW - SPARC

UR - http://www.scopus.com/inward/record.url?scp=85085957688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085957688&partnerID=8YFLogxK

U2 - 10.1016/j.plabm.2020.e00171

DO - 10.1016/j.plabm.2020.e00171

M3 - Article

C2 - 32548230

AN - SCOPUS:85085957688

SN - 2352-5517

VL - 21

JO - Practical Laboratory Medicine

JF - Practical Laboratory Medicine

M1 - e00171

ER -

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this